QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study

The objective of the study was to evaluate the clinical impact of QTc prolongation and the number of cardiac events in patients receiving Bdq/Dlm treatment for MDR-TB in treatment centres of the Tuberculosis Network European Trialsgroup (TBnet), a clinical research collaboration of the European Respiratory Society, within the World Health Organization (WHO) Europe region.

Source: European Respiratory Journal - August 16, 2018 Category: Respiratory Medicine Authors: Guglielmetti, L., Tiberi, S., Burman, M., Kunst, H., Wejse, C., Togonidze, T., Bothamley, G., Lange, C., for the TBnet Tags: Original Articles: Research letters Source Type: research